FIGS Boston Consulting Group Matrix

FIGS has built a formidable brand identity, resonating deeply with healthcare professionals. This strong connection fosters a loyal community, translating into exceptional word-of-mouth marketing and customer retention.

As of March 31, 2025, FIGS boasted 2.7 million active customers, a testament to its widespread appeal and the emotional bond it shares with its audience. This robust customer base directly supports its significant market share.

The brand's ability to create such a profound connection with its customers significantly reduces customer acquisition costs. This deep-seated loyalty acts as a powerful engine for sustained growth and market dominance.

FIGS' core premium scrub lines are the undisputed stars of their product portfolio. These aren't just any scrubs; they're recognized for cutting-edge fabric technology and fashionable aesthetics, solidifying FIGS' position as a market leader in the premium medical apparel space. While overall company growth might seem modest, with 1.8% in 2024 and a projected 5% in Q1 2025, the scrubwear segment continues to see revenue increases, demonstrating enduring customer loyalty and market command.

The brand's ability to create such a profound connection with its customers significantly reduces customer acquisition costs. This deep-seated loyalty acts as a powerful engine for sustained growth and market dominance, as evidenced by their 2.7 million active customers as of March 31, 2025.

FIGS' direct-to-consumer (DTC) e-commerce model is a cornerstone of its success, allowing for direct customer relationships and bypassing traditional retail channels. This agility has been key in disrupting the established medical apparel industry and solidifying FIGS' market presence, with an increased average order value (AOV) of $119 reported in Q1 2025.

Strategic partnerships, like outfitting over 250 Team USA healthcare professionals for the 2024 Olympic and Paralympic Games, significantly boost brand awareness and credibility on a global platform, reinforcing its premium image and driving market share expansion.

FIGS' established accessory products, like their popular compression socks and basic underscrubs, are prime examples of Cash Cows. These items have a strong foothold in the market, consistently bought by healthcare professionals.

These accessories act as excellent complements to FIGS' core scrub sales, driving cross-selling and providing a steady, reliable income stream. Their predictable revenue generation makes them highly efficient cash generators for the company.

Compared to launching new products, these established accessories demand less marketing investment, further enhancing their profitability. For instance, in 2024, FIGS reported that their accessory segment, which includes these items, contributed significantly to their overall revenue growth.

FIGS' core scrub collections and foundational accessories, like compression socks, are the company's established Cash Cows. These products benefit from high market share and strong customer loyalty, requiring minimal investment to maintain their appeal. For example, in Q1 2024, FIGS reported a gross profit margin of 65.2%, showcasing the profitability of these mature offerings.

The direct-to-consumer model further enhances the cash-generating capabilities of these items. By controlling the supply chain and optimizing operations, FIGS achieves high-profit margins. The company's approximately 2.7 million active customers in early 2024 contribute to predictable revenue streams from repeat purchases of these reliable products.

These Cash Cows, characterized by their consistent sales and high profitability, provide the stable financial foundation for FIGS. This allows the company to allocate resources towards growth initiatives, confident in the ongoing cash flow generated by its well-established product lines. In 2023, FIGS' net revenue reached $594.6 million, with a substantial portion stemming from these core, high-performing items.

Inefficient promotional strategies, if they fail to build lasting customer relationships or boost margins, can be classified as Dogs in the BCG framework. For FIGS, this could manifest as deep discounts that attract one-time buyers but don't foster loyalty, ultimately hurting profitability. For instance, if a significant portion of sales in 2024 came from heavily discounted items that barely covered costs, it would indicate an inefficient promotional approach.

Dogs in the BCG matrix for FIGS represent products with low market share and low growth potential. These are typically older, less popular styles or colors that are no longer in high demand. For instance, if a specific scrub color that was popular in 2022 only accounted for 2% of FIGS' sales in the first half of 2024, it would likely be classified as a Dog.

These items often result in excess inventory and may require significant markdowns to clear. The capital tied up in these products could be better utilized elsewhere. If FIGS has over 10% of its inventory in styles that haven't seen a sales increase in over a year, it indicates a significant Dog portfolio.

Managing these Dogs involves strategies like liquidation or discontinuation to free up resources. For example, FIGS might offer these items at a steep discount during a seasonal sale to reduce stock levels. By the end of 2024, if these products continue to underperform, a strategic decision to phase them out entirely would be prudent to improve overall inventory turnover and profitability.

FIGS' strategic push into markets like Japan and South Korea in 2025 represents a significant opportunity, considering that over 80% of healthcare professionals globally operate outside the United States. This aggressive international expansion targets regions with substantial untapped demand for premium healthcare apparel.

However, FIGS' current footprint in these specific markets is minimal, meaning their market share is nascent. This presents a classic "question mark" scenario in the BCG matrix, where high potential growth exists but requires substantial strategic investment to capitalize on.

To convert this potential into tangible market share, FIGS will need to allocate significant capital towards localized marketing campaigns, robust distribution networks, and efficient logistics. These investments are crucial for navigating market entry barriers and establishing a strong brand presence in these competitive landscapes.

FIGS' international expansion into markets like Japan and South Korea in 2025 positions these ventures as Question Marks. With over 80% of healthcare professionals globally outside the U.S., these regions offer substantial untapped demand, but FIGS' current market share is minimal, necessitating significant investment in localized marketing and distribution to gain traction.

The company's foray into smart fabrics with integrated wearable technology also falls into the Question Mark category. While the smart textile sector is projected for robust growth, reaching an estimated $7.5 billion by 2027, FIGS' current share in this technologically advanced niche is negligible, requiring substantial R&D and capital expenditure to navigate technological and adoption risks.

FIGS' new 'Community Hubs' physical retail strategy, with three locations planned for H2 2025, represents another Question Mark. This omnichannel approach aims to boost customer acquisition and brand immersion, but its profitability and scalability compared to the dominant DTC model remain unproven, requiring significant investment to establish a strong physical presence.

The TEAMS program, targeting institutional B2B sales within the U.S. healthcare apparel market, is also a Question Mark. While this segment comprises an estimated 15% of the U.S. scrubs market, FIGS faces established competitors and needs to adapt its sales approach for longer cycles and distinct procurement processes to capture market share.